Account
Inquiry
Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist being developed for type 2 diabetes research. This white powder formulation shows superior efficacy in glucose control and weight management studies compared to selective GLP-1 agonists.
The molecular structure of Tirzepatide features a PEG-modified lysine side chain that enhances water solubility. Clinical trials have demonstrated significant weight reduction effects, with average losses of 15-20% body weight at different dosage levels over 72 weeks.
As a once-weekly administered compound, Tirzepatide represents an innovative approach in metabolic research by combining the effects of two incretin hormones into a single molecule. The product is supplied as a lyophilized powder in sealed vials to maintain stability.
Proper storage is essential for maintaining peptide integrity. We recommend storing Tirzepatide in a cool, dry environment protected from light and moisture. Avoid repeated freeze-thaw cycles and prolonged exposure to air when handling.
This product is intended for research purposes only and not for human consumption. Researchers should follow all applicable laboratory safety protocols when handling this material.
